Join NETRF’s ‘Research Changes Lives’ Giving Tuesday Campaign—Every gift doubled now through December 3, 2024. LEARN MORE
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The U.S. Food and Drug Administration recently authorized a new technology called histotripsy to treat tumors in the liver, including neuroendocrine tumors. The noninvasive Edison®
In 2019, Claire Mulvey, MD, received a NETRF Mentored Research Award to study the trends in incidence and survival outcomes for lung NETs. The goal
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to announce its 2024 Request for Applications. We’re seeking transformative research proposals in basic, translational, and clinical
Lutathera®, when given with long-acting release octreotide, reduces the risk of disease progression or death in those with newly diagnosed Grade 2 and 3 advanced
U.S. & International Scientists to focus on drug therapies, radiopharmaceuticals, and progression of NETs [BOSTON, MA, January 17, 2024–] The Neuroendocrine Tumor Research Foundation (NETRF)
Lung neuroendocrine tumors (NETs) are graded as typical or atypical carcinoids based on how quickly the tumor cells divide. They exhibit diverse clinical behaviors and
Midgut neuroendocrine tumors (NETs), such as small intestinal NETs, originate in the neuroendocrine cells of the midgut, a part of the digestive system, and have
The initial findings of a Phase 2 study have shown that the investigational drug paltusotine may significantly reduce both the frequency and intensity of bowel
As we reflect on the past year, the Neuroendocrine Tumor Research Foundation (NETRF) takes immense pride in the strides we have made towards understanding and
NETRF’s 2023 Margie and Robert E Petersen Neuroendocrine Tumor Research Symposium brought together a hundred of the world’s foremost neuroendocrine cancer scientists in Boston. The
